Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38581017)

  • 1. Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy.
    Shen W; Li Y; Yang Z; Li W; Cao Y; Liu Y; Wang Z; Pei R; Xing C
    J Nanobiotechnology; 2024 Apr; 22(1):154. PubMed ID: 38581017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transformable prodrug nanoplatform
    Yang W; Yi J; Zhu R; Guo Y; Zhang K; Cao Y; Li X; Zhang J; Zhang Z; Li Y; Chen X
    Theranostics; 2023; 13(6):1906-1920. PubMed ID: 37064869
    [No Abstract]   [Full Text] [Related]  

  • 3. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
    Xie L; Wang G; Sang W; Li J; Zhang Z; Li W; Yan J; Zhao Q; Dai Y
    Biomaterials; 2021 Feb; 269():120638. PubMed ID: 33421711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
    Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
    Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
    Eskandari-Malayeri F; Rezaei M
    Front Immunol; 2022; 13():996145. PubMed ID: 36275750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
    Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
    Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief.
    He M; Zhang M; Xu T; Xue S; Li D; Zhao Y; Zhi F; Ding D
    J Control Release; 2024 Apr; 368():233-250. PubMed ID: 38395154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.
    He ZD; Zhang M; Wang YH; He Y; Wang HR; Chen BF; Tu B; Zhu SQ; Huang YZ
    Acta Pharmacol Sin; 2021 Sep; 42(9):1516-1523. PubMed ID: 33311600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
    Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
    Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition.
    Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing TNBC Chemo-immunotherapy via combination reprogramming tumor immune microenvironment with Immunogenic Cell Death.
    Wu S; Liu D; Li W; Song B; Chen C; Chen D; Hu H
    Int J Pharm; 2021 Apr; 598():120333. PubMed ID: 33540008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
    Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
    J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
    Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
    Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors.
    Huang Y; Chen Y; Zhou S; Chen L; Wang J; Pei Y; Xu M; Feng J; Jiang T; Liang K; Liu S; Song Q; Jiang G; Gu X; Zhang Q; Gao X; Chen J
    Nat Commun; 2020 Jan; 11(1):622. PubMed ID: 32001695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomineralized MnO
    Deng Z; Xi M; Zhang C; Wu X; Li Q; Wang C; Fang H; Sun G; Zhang Y; Yang G; Liu Z
    ACS Nano; 2023 Mar; 17(5):4495-4506. PubMed ID: 36848115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
    Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
    Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
    Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
    J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
    Qi J; Jin F; Xu X; Du Y
    Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.